Consolidated Statement Of Cash Flows

Modalis Therapeutics Corporation - Filing #7272022

Concept 2024-01-01 to
2024-12-31
As at
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-1,316,929,000 JPY
-1,440,117,000 JPY
-2,401,334,000 JPY
-2,390,607,000 JPY
Depreciation
JPY
731,000 JPY
Impairment losses
188,000 JPY
38,818,000 JPY
Interest and dividend income
-102,000 JPY
-25,000 JPY
Interest expenses
3,857,000 JPY
4,414,000 JPY
Foreign exchange losses (gains)
-61,558,000 JPY
-27,860,000 JPY
Subtotal
-1,413,398,000 JPY
-2,248,867,000 JPY
Income taxes paid
-1,210,000 JPY
-1,210,000 JPY
Net cash provided by (used in) operating activities
-1,432,005,000 JPY
-2,254,466,000 JPY
Other, net
41,540,000 JPY
60,135,000 JPY
Interest and dividends received
102,000 JPY
25,000 JPY
Interest paid
-3,857,000 JPY
-4,414,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-188,000 JPY
-39,699,000 JPY
Net cash provided by (used in) investing activities
-188,000 JPY
-39,699,000 JPY
Cash flows from financing activities
Net cash provided by (used in) financing activities
3,044,985,000 JPY
1,216,451,000 JPY
Other, net
JPY
-600,000 JPY
Effect of exchange rate change on cash and cash equivalents
79,047,000 JPY
27,989,000 JPY
Net increase (decrease) in cash and cash equivalents
1,691,839,000 JPY
-1,049,725,000 JPY
Cash and cash equivalents
3,575,277,000 JPY
1,883,437,000 JPY
2,933,162,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.